When that information is gained, the combined therapeutic approach obtained by blocking NF-κB and inducing the apoptotic response may result in the most favorable outcome possible for non-GCB DLBCL patients. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.